# Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

> **NCT05924672** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of California, San Francisco** · enrollment: 2 (actual)

## Conditions studied

- Castration-Resistant Prostate Carcinoma
- Metastatic Malignant Neoplasm in the Bone
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **DRUG:** Radium-223
- **PROCEDURE:** PSMA Positron Emission Tomography (PET) Scan
- **DRUG:** Technetium Tc 99M Medronate

## Key facts

- **NCT ID:** NCT05924672
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-30
- **Primary completion:** 2026-01-07
- **Final completion:** 2027-03-31
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2026-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05924672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05924672, "Efficacy of Ra-223 in PSMA PET Optimally Selected Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05924672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*